Diary - News
All news Advanced BioDesign joins ENHPATHY consortium
Consortium gathers 27 organizations from 11 countries to work on enhanceropathies; will receive €4M from European Commission over next four years
Lyon, France, January 21, 2020 – Advanced BioDesign, a French pre-clinical stage biotechnology company focused on the development of a new treatment against resistant cancers, today announces it has teamed up with 27 European academic and industrial organizations from 11 countries to form the multidisciplinary science consortium, ENHPATHY.
